A clinical study to evaluate the efficacy of Rhus toxicodendron at 200th potency on knee joints of osteoarthritis patients.

A study on cartilage oligomeric matrix protein gene expression in patients suffering from osteoarthritis of knee treated with Rhus toxicodendron 200th potency - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/09/058093

Enrollment

Registered

2023-09-27

Start date

Unknown

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M179- Osteoarthritis of knee, unspecified

Interventions

Intervention1: Rhus toxicodendron medicine in 200th potency: All the patients complying with the characteristic features of Rhus toxicodendron will be selected and prescribed with 200th potency TDS fo

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients with frequent knee symptoms in the past three months defined as “pain, aching or stiffness in or around the knee on most days ? for at least one month during the past three months. 2.Overweight or have two or more other eligibility risk factors The specific eligibility risk factor criteria for the incidence will be •Frequent knee symptoms. •Frequent use of medication on most days of a month in the past 12 months. •Radiographic OA compared to knee without symptoms. •Knee injury, defined as a history of knee injury causing difficulty walking for atleast a week. 3.Age group: 35 to 80 yrs. 4.Sex: Both Males and Females. 5.Patients with symptomatology of Rhus toxicodendron

Exclusion criteria

Exclusion criteria: 1.Patients suffering from other severe systemic diseases. 2.Age group: Below 35 yrs. and above 80 yrs. 3.Patients with symptoms of medicines other than Rhus toxicodendron. 4.Bilateral total knee joint replacement or plans to have bilateral knee replacement in the next 3 years. 5.Pregnancy 6.Unwilling to sign informed consent.

Design outcomes

Primary

Measure	Time frame
Post interventional WOMAC Index assessment for pain reduction and improvement in mobiity Gene Expression study Timepoint: Post interventional WOMAC Index assessment for pain reduction and improvement in mobiity after treatment period of 6 weeks Gene Expression study after treatment period of 6 weeks	—

Secondary

Measure	Time frame
alleviation in clinical symptoms of Osteoarthritis of knee jointTimepoint: after treatment period of 6 weeks	—

Countries

India

Contacts

Public ContactDrWinston varghese

sarada krishna homoeopathic medical college

drwinstonv@gmail.com9443692478

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026